NEWS: MAY 2004

-5/28/2004-

FDA approves Indevus Pharmaceuticals Inc.'s drug Sanctura for overactive bladder. To read article click here.

Genta Inc. and Aventis officially stop Genasense™ drug program. To read article click here.

-5/27/2004-

Press Release: HomelandDefenseStocks.com's latest report: “Is the nation ready for a ‘dirty bomb?To read press release click here.

Alnylam Pharmaceuticals Inc. goes IPO. To read article click here.

Shire BioChem Inc. bails out from ImmunoGen Inc. To read article click here.

Invitrogen to launch first proteome microarray at BIO 2004. To read article click here.

-5/26/2004-

ACADIA Pharmaceuticals Inc. goes IPO. To read article click here.

Human Genome Sciences Inc. initiates Phase II clinical trials of Albuferon™ (albumin-interferon alpha) for chronic hepatitis C. To read article click here.

SciClone Pharmaceuticals Inc. and Nektar Therapeutics form collaborationto develop pegylated formulation of ZADAXIN®. To read article click here.

Pharmaceutical Resources Inc. changes its name to Par Pharmaceutical Companies Inc. To read article click here.

Barrier Therapeutics Inc. initiates Phase III clinical trials for Sebazole™ for seborrheic dermatitis treatment. To read article click here.

Allergan Inc.and Kyorin Pharmaceutical Co. Ltd. sign agreement to develop and market ALPHAGAN®/ALPHAGAN® P in Japan. To read article click here.

Anadys Pharmaceuticals Inc. selects ANA975 to develop for chronic hepatitis C virus (HCV) infection. To read article click here.

Concurrent Pharmaceuticals Inc. acquires rights to Allergan Inc.'s retinoid program. To read article click here.

-5/25/2004-

Press Release: Radleys Discovery Technologies, specialists in parallel chemistry, have introduced new and enhanced software for their Metz Syn10 controlled personal synthesiser. To read press release click here.

Press Release: With a wide choice of designs and formats the Krystal clear-bottomed microplate range from Porvair Sciences offers an optimised plate to suit almost all photometric and cell counting applications. To read press release click here.

Press Release: Genetix offers a choice of 96 or 384 pin replicators for compound transfer in clone library replication and manipulation applications. To read press release click here.

FDA suspends Dyax's clinical trials of DX-88 for the treatment of hereditary angiodema. To read article click here.

Elan and Biogen Idec submit to the FDA drug Antegren for for approval to treat multiple sclerosis. To read article click here.

-5/24/2004-

Press Release: Genetronics and Merck Sign Licensing Agreement for MedPulser(R) DNA Delivery System to Support DNA Vaccine Delivery. To read press release click here.

Tripos Inc. releases LITHIUM™ 2.0 for data exchange and visualization. To read article click here.

Titan Pharmaceuticals Inc. initiates two Phase II clinical trials of Pivanex for refractory chronic lymphocytic leukemia and refractory malignant melanoma treatment. To read article click here.

Vertex Pharmaceuticals Inc. and Cystic Fibrosis Foundation Therapeutics Inc. expand drug discovery and development collaboration. To read article click here.

Rigel Pharmaceuticals Inc. initiates Phase I/II clinical trials of R803 for Hepatitis C Virus (HCV). To read article click here.

-5/21/2004-

Press Release: Guava Technologies, a leading supplier of integrated cellular analysis systems for life science research, has reported an enthusiastc response from researchers around the world to a series of informative webcasts that it has recently broadcast. To read press release click here.

Poland's anti-monopoly office gives thumbs up to Ivax for the acquisition of Polfa Kutno. To read article click here.

Savient Pharmaceuticals Inc.'s CEO to retire. To read article click here.

MultiCell Technologies Inc. announces new human hepatocyte cell lines for drug discovery and toxicity tests. To read article click here.

Lynx Therapeutics Inc. and the National Institute of Mental Health form collaboration to study gene expression in the brain. To read article click here.

-5/20/2004-

Pharmacopeia Inc. changes its name to Accelrys Inc. To read article click here.

Innovative Companies Inc. changes its name to GeoPharma Inc. To read article click here.

FDA approves Pharmion's Vidaza for the treatment of myelodysplastic syndromes. To read article click here.

ZymoGenetics Inc. licenses metabolic disease target patent to Amgen Inc. To read article click here.

Verdia Inc. publishes in the journal Science the development of a novel glyphosate-resistant gene. To read article click here.

Biomira Inc. and Inno-Centre Alberta create spin- off company: Oncodigm BioPharma Inc. To read article click here.

Boston Life Sciences Inc. initiates Phase III clinical trials of Altropane® to differentiate Parkinsonian from non-Parkinsonian tremors. To read article click here.

-5/19/2004-

Press Release: Radleys Discovery Technologies, a leading developer of solutions for parallel chemistry, has announced the launch of a completely new and comprehensively featured website. To read press release click here.

Press Release: Porvair Sciences, specialists in microplate technology, have introduced a new range of Reservoir Trays designed for use with any robotic liquid handling system. To read press release click here.

Press Release: Genetix have announced a new on-line guide introducing an automated methodology that significantly accelerates the production of high titre monoclonal antibodies and protein biologicals using mammalian cells in cultures. To read press release click here.

Affymetrix Inc. and ParAllele BioScience sign alliance agreement. To read article click here.

FDA approves SkyePharma PLC and Endo Pharmaceuticals' New Drug Application (NDA) for DepoDur™ for the treatment of post-surgery pain. To read article click here.

-5/18/2004-

Press Release: Available from Genevac the EZ-2 HCl centrifugal evaporator provides laboratories with a highly efficient and safe means of routinely removing strongly acidic chemicals from their samples. To read press release click here.

Press Release: Tecan Europe has announced the availability of a technical brochure describing its wide range of systems, modules and protocols utilising the latest technologies for automated Nucleic Acid and PCR or Sequencing reaction preparation. To read press release click here.

UCB to buy Celltech for $2.7 billion. To read article click here.

Elan Corporation sells Frova™ (frovatriptan) to the Vernalis Group. To read article click here.

Elan Corp and Biogen Idec Inc.'s experimental drug Antegren gives positive results for Crohn's disease treatment. To read article click here.

Chiron Corporation begins Phase III clinical trial of Tifacogin for severe community-acquired pneumonia treatment. To read article click here.

-5/17/2004-

Millennium Pharmaceuticals Inc.'s Velcade® for bone cancer gives very good results in late-stage clinical trials. To read article click here.

King Pharmaceuticals Inc.'s CEO leaves the company. To read article click here.

Chiron Corp. spins off PowderMed Ltd. To read article click here.

-5/14/2004-

Targacept Inc. goes IPO. To read article click here.

Introgen Therapeutics Inc.'s non-viral gene delivery system supports sustained gene expression in an experimental lung cancer model. To read article click here.

-5/13/2004-

Press Release: ESA, an international supplier of bio-analytical instrumentation, has developed the Metabolomics System, a powerful new advance utilising ESA's proven electrochemical (EC) technology, to simplify and increase the efficiency of metabolomics studies. To read press release click here.

Press Release: INTEGRA Biosciences has announced that Mr Vito Noto, the designer of its popular PIPETBOY Comfort precision pipette, has been awarded an entry in the prestigious Associazione per il Disegno Industriale 2003 (ADI Design Index). To read press release click here.

Genta Inc. withdraws FDA application for its experimental drug Genasense for the treatment of advanced melanomac and cuts its work force by 45 percent. To read article click here and here.

Syntonix Pharmaceuticals Inc. and Dyax Corp. form antibody discovery collaboration. To read article click here.

InterMune Inc. initiates Phase II clinical trials of Infergen® in combination with Actimmune® for the treatment of hepatitis C virus (HCV). To read article click here.

Access Pharmaceuticals Inc. signs second B12 oral drug delivery research collaboration. To read article click here.

The Walter Reed Army Institute of Research initiates Phase I clinical trials of AVANT Immunotherapeutics Inc.'s HIV vaccine. To read article click here.

Evotec OAI AG and Guilford Pharmaceuticals Inc. form drug discovery collaboration. To read article click here.

Cytokinetics Inc.-GlaxoSmithKline's kinesin spindle protein inhibitor SB-743921 goes to Phase I clinical trials for treatment of solid tumors. To read article click here.

Gene Logic Inc. to provide the FDA gene expression data set from vehicle-treated rat liver samples. To read article click here.

Millennium Pharmaceuticals Inc. initiates Phase II clinical trials of VELCADE® (bortezomib) in combination with rituximab fo indolent non-Hodgkin's lymphoma treatment. To read article click here.

-5/12/2004-

Phase III clinical trails of Maxim Pharmaceuticals's Celpene for leukemia treatment affords positive results. To read article click here.

Evotec OAI AG and Roche form discovery chemistry collaboration. To read article click here.

GlycoGenesys Inc. initiates Phase II clinical trials of GCS-100LE for multiple solid tumor cancer treatment. To read article click here.

Novogen initiates Phase Ia clinical trails of NV-18 for cancer treatment. To read article click here.

Ingenium Pharmaceuticals AG acquires US patents 5,994,075 and 6,015,670 from Incyte Corp. To read article click here.

-5/11/2004-

Incyte Corporation initiates Phase I clinical trials of its oral CCR2 antagonist compound INCB3284. To read article click here.

Introgen Therapeutics Inc. receives U.S. patent 6,726,907, entitled "Purified Adenovirus Compositions." To read article click here.

-5/10/2004-

Guilford Pharmaceuticals Inc. initiates Phase III clinical trails for AQUAVAN® Injection. To read article click here.

Sysmex Corporation initiates clinical trials of NMP179™ for cervical cancer in women. To read article click here.

Bentley Pharmaceuticals Inc. acquires in Spain FDA-approved active pharmaceutical ingredient manufacturing facility. To read article click here.

Bionomics and PerkinElmer Inc. form GPCR and Ion Channel research collaboration. To read article click here.

-5/07/2004-

Albany Molecular Research Inc. wins 3-year contract by the National Institute on Drug Abuse. To read article click here.

Curis Inc.'s compound BMP-7 stimulates dopamine levels in Parkinson's disease model. To read article click here.

FDA bars over counter morning-after pill. To read article click here.

-5/06/2004-

Amgen Inc. gets US antitrust approval for its acquisition of Tularik Inc. To read article click here.

Eli Lilly and Co. and Isis Pharmaceuticals Inc. extend cancer drug discovery collaboration. To read article click here.

Dr. Reddy's Laboratories acquires Trigenesis Therapeutics Inc. To read article click here.

NeoPharm initiales Phase I/II clinical trials of IL13-PE38QQR for cancer. To read article click here.

-5/05/2004-

Tanox Inc. initiates Phase II clinical trials of TNX-355 for HIV treatment. To read article click here.

CombinatoRx to screen Immtech International Inc.'s compounds DB289 and DB75 against various cancers. To read article click here.

-5/04/2004-

Cytokinetics Inc. goes IPO. To read article click here.

FDA rejects Aventis' Genasense injection drug for advanced melanoma. To read article click here.

NaPro BioTherapeutics Inc. changes its name to Tapestry Pharmaceuticals Inc. To read article click here.

Albany Molecular Research Inc. to close a research center near Chicago. To read article click here.

Lorus Therapeutics Inc. initiates Phase I clinical trials of GTI-2040 for colon cancer. To read article click here.

4SC AG and Serono form alliance to develop and commercialize dihydroorotate dehydrogenase inhibitors. To read article click here.

-5/03/2004-

Pharmacopeia completes spin-off of Pharmacopeia Drug Discovery. To read article click here.

Soybean protein peptide may inhibit the growth of tumor cells. To read article click here.

FDA grants Orphan Drug Status to Progen Industries Limited's PI-88 for treatment of malignant melanoma. To read article click here.